Literature DB >> 6469936

Naltrexone treatment for addicted health-care professionals: a collaborative private practice experience.

W Ling, D R Wesson.   

Abstract

Sixty physicians and other health-care professionals with narcotic dependency were treated with naltrexone, 300 to 350 mg/week, in private physicians' offices. Patients remained on naltrexone treatment for an average of 8 months. On a global scale rating the degree of improvement in drug abuse, professional activities, and psychosocial adjustment, 29 patients were rated much improved and 31 either moderately or slightly improved. When these two groups were compared, it was found that more patients in the much improved group did not drink (p less than .01) and remained in naltrexone treatment longer than 6 months (p less than .01). Patients in the much improved group were also older (p less than .01). Naltrexone, used in the private practice setting, appears to be a useful treatment adjunct for addicted health-care professionals.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6469936

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  13 in total

Review 1.  Oral naltrexone maintenance treatment for opioid dependence.

Authors:  Silvia Minozzi; Laura Amato; Simona Vecchi; Marina Davoli; Ursula Kirchmayer; Annette Verster
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

2.  A categorical typology of naltrexone-adopting private substance abuse treatment centers.

Authors:  Carrie B Oser; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2007-11-07

Review 3.  Maintenance medication for opiate addiction: the foundation of recovery.

Authors:  Gavin Bart
Journal:  J Addict Dis       Date:  2012

4.  Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial.

Authors:  Evgeny Krupitsky; Elena Blokhina; Edwin Zvartau; Elena Verbitskaya; Dmitri Lioznov; Tatiana Yaroslavtseva; Vladimir Palatkin; Marina Vetrova; Natalia Bushara; Andrei Burakov; Dmitri Masalov; Olga Mamontova; Daniel Langleben; Sabrina Poole; Robert Gross; George Woody
Journal:  Lancet HIV       Date:  2019-03-14       Impact factor: 12.767

Review 5.  The role of naltrexone in the management of drug abuse.

Authors:  H M Ginzburg; M G MacDonald
Journal:  Med Toxicol       Date:  1987 Mar-Apr

6.  (R)-methadone versus racemic methadone: what is best for patient care?

Authors:  Elinore F McCance-Katz
Journal:  Addiction       Date:  2011-04       Impact factor: 6.526

Review 7.  Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals.

Authors:  Jeanette M Tetrault; David A Fiellin
Journal:  Drugs       Date:  2012-01-22       Impact factor: 9.546

8.  Effects of incentives for naltrexone adherence on opiate abstinence in heroin-dependent adults.

Authors:  Brantley P Jarvis; August F Holtyn; Anthony DeFulio; Kelly E Dunn; Jeffrey J Everly; Jeannie-Marie S Leoutsakos; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman
Journal:  Addiction       Date:  2017-02-03       Impact factor: 6.526

9.  A randomized trial of oral naltrexone for treating opioid-dependent offenders.

Authors:  Donna M Coviello; James W Cornish; Kevin G Lynch; Arthur I Alterman; Charles P O'Brien
Journal:  Am J Addict       Date:  2010 Sep-Oct

Review 10.  Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.

Authors:  J P Gonzalez; R N Brogden
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.